• Fri news: Gilead withdraws bladder cancer drug. Amgen and Intercept PDUFA date pushback. CVS replaces CEO. Supernus depression trial. AbbVie Parkinson’s approval. See more on our front page

Its only a matter of time before Gilead is TOAST!!!

Diligence
One who is the last to reduce the invention to practice but the first to conceive of the invention may establish priority by showing continuous and reasonable diligence (i.e., activities) towards reduction to practice, during the critical period from just before the other person’s conception until his own reduction to practice.

Diligence is a stringent standard and most of the inventor’s time must be spent developing the invention. Constant effort is not required and the inventor need not spend all of his time working on the invention. But the inventor must account for the entire critical period by showing either activity aimed at reduction to practice or legally adequate excuses for the inactivity (e.g. reasonable delays in receiving ordered parts, purchasing capital equipment or requesting technical services).

Most excuses for gaps in the record of invention will not be accepted within the diligence standard.
 




Reduction to Practice of Invention

There are two types of reduction to practice: actual and constructive. An actual reduction to practice takes place when the invention is made and successfully tested in the United States, Canada or Mexico in a manner which shows that the invention will be useful for the purpose for which it was made.

A constructive reduction to practice occurs when an application for the invention is filed in the United States or, in the case of applications entitled to the benefit of foreign priority, on the date that the foreign (e.g., Japanese) application was filed.

The successful demonstration (i.e., testing), usually at a company, of an invention is known as “actual reduction to practice”. The date of the first actual reduction to practice is generally the most important date in establishing priority and originality of an invention, especially in an interference proceeding (Patent Office priority of invention contest).

An inventor cannot by his own uncorroborated testimony prove his date of reduction to practice, nor can that date be corroborated by a co-inventor of the invention. The dates must be corroborated by independent evidence such as the testimony of a non-inventor witness (for example, another company employee) or contemporary business records (e.g., laboratory notebooks) which are sufficiently believable to convince the court that the inventor’s testimony is true. A “rule of reason” test is applied by U.S. courts in evaluating the corroborative evidence.

There is no one formula for corroborating the inventor’s testimony; however, we recommend that inventors use physical notebooks containing explicit, dated, signed and witnessed permanent records of invention conception, reduction to practice and each of the steps taken or that could be taken by one of ordinary skill in the art to reduce the invention to practice. Thus, company engineers should maintain their Notebooks according to the following system:
 




yup, I posted the links. All the "evidence" is there. Judge for yourself. See the concluding remarks from the last trial where both sides "bring it home" with their summary of arguments. I still say that anyone that is not worried about a Jury trial is lying or just does not know the evidence. Gilead is currently marketing at Risk until this gets settled one way or another. If (I said if) they lose at this point...It could cost them their company (when considering the amount of dollars here (remember the 3X penalties). My conclusion...at some point a settlement will be made. Again, its worth the discussion.
 




Your non-stop analysis means nothing. If there was anything to what you are saying then the stock would be at 50 or more and Analysts would be giving the "red flag of caution" when discussing Gilead's future. There has been not one word about anything you talk about: Bottom Line-You are wrong.

Go Gilead!! Forever!! Keep buying GILD stock if your smart!!
 












Absolutely good news for Idenix:Order—Request for Panel Rehearing—Bd.R. 125(c)(5)

(1) Junior Party Jeremy Clark (“Clark”) has requested a rehearing by the panel (hereinafter the “Request”1) of the April 11, 2014 Decision on Storer’s Response to the Board’s Order to Show Cause (hereinafter the “Decision”) which concluded that Storer had shown sufficient cause why judgment should not be entered against it at that time. Decision at (3). Specifically, the Board concluded that, because Storer had filed an action in the U.S. District Court of Delaware seeking review of the Board’s judgment in interference No. 105,8714 (the “’871 interference) under 8 35 U.S.C. § 146, the Board’s judgment in that interference was not final and that Storer was not barred by interference estoppel or issue preclusion from arguing that its involved claims were not unpatentable for lack of enablement under 35 11 U.S.C. § 112. Id. Clark now seeks rehearing of the Decision by the panel.
(2)Clark argues that the Decision overlooked or misapprehended that, notwithstanding the pendency of a § 146 action, the doctrine of interference estoppel attaches upon judgment in a first interference and precludes a party that loses that first interference from relitigating in a second interference any issue that it raised (or could have raised) in the first interference. Request at 2 (citing Bd.R. 19 127(a)(1)). Specifically, Clark points out to Bd.R. 127 which provides that:
(a) Effect within Office—
Estoppel. A judgment disposes of all issues that were, or by motion could have properly been, raised and decided. A losing party who could have properly moved for relief on an issue, but did not so move, may not take action in the Office after the judgment that is inconsistent with that party’s failure to move, except that a losing party shall not be estopped with respect to any contested subject matter for which that party was awarded a favorable judgment.
Bd.R. 127(a)(1) (emphasis added by Clark). According to Clark, once judgment issues, interference estoppel is immediately triggered within the Patent Office. Request at 4. (citing, e.g., Dawson v. Dallavalle, Interference No. 105,569, Paper No. 43, Judgment, p. 5:10-11 (B.P.A.I. Sept. 18, 2007) (“[w]hen a judgment is entered in an interference, the estoppel provisions of 37 C.F.R. § 41.127(a) become applicable.”)).

Clark argues that this construction is consistent with the interference rules’ goal; viz., the just, speedy, and inexpensive resolution of every proceeding before the Board. Request at 4 (citing Bd.R. 1(b)). Clark contends that entry of judgment against Storer in the present interference benefits not only Clark, but also the Board and the public. Request at 4. Indeed, argues Clark, the fact that Storer has sought court review of the Board’s decision confirms that the estoppel provisions of Bd.R. 127(a)(1) were triggered because district court review is only proper once the Board enters judgment that disposes of all the issues that were, or by motion could have properly been, raised and decided. Id.at 4-5. (citing, e.g., Human Genome Sciences, Inc. v. Genentech, Inc., 589 F.Supp.2d 512, 519 (D. Del. 2008) (“District courts may only review a final judgment by the Board, disposing of all 27 issues that were, or by motion could have properly been, raised and decided”).

Clark maintains that Bd.R. 127 does not create any exception to estoppel in instances when the Board’s decision is undergoing district court review pursuant to 2 § 146. Request at 5. Rather, argues Clark, the rule explicitly states that the prior judgment has estoppel effect “within the Office.” Id. According to Clark, the fact that there may be further proceedings before some other tribunal—either a district court or the Federal Circuit—is irrelevant under the text of Bd.R. 127(a)(1). Id. Clark argues that once the Board issues judgment in a first interference, it would be a waste of resources for the Office to consider the same or substantially identical issue in a second interference just because the first decision is under judicial review. Id. Instead, argues Clark, the rules provide that the Board should apply interference estoppel in the second interference, enter judgment to that effect, and permit both decisions to receive judicial review simultaneously, thereby conserving Board resources. Id. Clark argues further that the Board erroneously relied on In re Deckler, 977 14 F.2d 1449 (Fed. Cir. 1992) as demonstrating that Storer should not be estopped by interference estoppel or issue preclusion because the decision in the ’871 16 Interference was not yet final. Request at 5. Clark argues that Deckler does not address the impact of a pending § 146 action on finality, but rather addressed an instance where the appellant had previously lost an interference, did not challenge the results of that interference, but subsequently, tried to challenge the result of the interference at the Federal Circuit after the claims were rejected in prosecution. Request at 6 (citing Deckler, 977 F.2d at 1450-51). According to Clark, the Federal Circuit held that interference estoppel applied where the appellant did not challenge the results of the interference or that his claims at issue were patentably indistinguishable from the lost interference count. Clark argues therefore that Deckler did not involve either a § 146 action or a situation where there were multiple interferences and that Deckler confirms the notion that interference estoppel is in harmony with the well-settled principles of res judicata and collateral estoppel.

CONTINUED.....
 




CONTINUED....
We are not persuaded by Clark’s arguments. As an initial matter, Clark’s citing of Dawson is inapposite, as Dawson did not address a situation in which a § 146 action had been filed subsequent to a decision of the Board. Rather, the Dawson panel stated that if, following the panel’s decision:
[A] reissue application is filed, the Examiner will undertake an examination of that reissue application. 35 U.S.C. § 131. If in the opinion of the Examiner, a rejection based on Deckler is appropriate, the Examiner is free to make the rejection notwithstanding any attempt by Dawson in the motion conceding priority to preempt action by the Examiner. 35 U.S.C. § 132. When a judgment is entered in an interference, the estoppel provisions of 37 C.F.R. § 41.127(a) become applicable. As the Board indicated in Kaufman v. Talieh, Interference 105,233, Paper 23, page 2 (Bd. Pat. App. & Int. Nov. 19, 2004) (Exhibit 1003), reservations made in concessions of priority do “not negate the effects of 37 CFR § 41.127 […] regarding interference estoppel.”

Dawson, p. 5, ll. 5-15. Dawson thus addresses whether the Examiner may apply estoppel in the examination of a reissue application after a final decision of the Board. Id. The issue that Clark has brought before the panel for rehearing is whether a judgment of the Board under Bd.R. 127(a)(1) in a first interference invokes Deckler-type estoppel or interference estoppel (issue preclusion) in a second, related interference, when a § 146 action has been filed in the first interference. Dawson does not address this issue at all; no § 146 action was filed subsequent to the judgment, and the Board’s ruling with respect to the Examiner’s possible finding of estoppel in a subsequent reissue examination, is not relevant to the question before the panel.

decision from precluding certain issues…; a judgment by an agency can have preclusive effect in subsequent lawsuits if the parties had a ‘full and fair opportunity to litigate’ and the agency rendered the decision while acting in a ‘judicial capacity.’” Abbott GMBH & Co., KG v. Centocor Ortho Biotech, Inc., 870 F.Supp.2d 206, 221 (D. Mass.,2012) (quoting United States v. Utah Constr. & Min. Co., 384 U.S. 394, 422 (1966)). When those requirements are fulfilled, the agency judgment will ordinarily have preclusive effect, provided that the prerequisites for preclusion outlined in Ramallo Bros. Printing, Inc. v. El Dia, Inc., 490 F.3d 86 (1st Cir. 2007) are present. Abbott, 870 F.Supp.2d at 221 (citing Global NAPs, Inc. v. Massachusetts Dep’t of Telecomm. & Energy, 427 F.3d 34, 14 44 (1st Cir.2005); Aunyx Corp. v. Canon U.S.A., Inc., 978 F.2d 3, 7 (1st Cir.1992). The Ramallo test states that the decision of one tribunal precludes re- litigation of the same issue in a subsequent lawsuit if “(1) the issue sought to be precluded in the later action is the same as that involved in the earlier action; (2) the issue was actually litigated; (3) the issue was determined by a valid and binding final judgment; and (4) the determination of the issue was essential to the judgment.” Ramallo, 490 F.3d at 90

I will skip now to the end...

We consequently conclude that, in the circumstances of this case, a judgment of the Board under Bd.R. 127(a)(1) is not a judgment sufficiently final to invoke an estoppel. Clark’s request for rehearing is granted to the extent that we have considered its arguments, but its request that we reverse the decision of the administrative patent judge is DENIED.
IT IS SO ORDERED



THIS IS THE DECISION THAT I WAS WAITING FOR: IN MY HUMBLE OPINION IT SHOWS US WHO WILL WIN THE SECOND INTERFERENCE (IDENIX). THEY WILL MAINTAIN SENIOR POSITION IN THIS INTERFERENCE AND THUS BE "ALLOWED" TO USE THEIR EARLIER DATED PATENTS.
 




The decision today is the one I referenced a while back. This decision, in my opinion, foretells how this trial will end....My suggestion is to be very very careful going forward.

Investors better start paying attention.
 








Incredible! Absolutely Amazing!

THIS IS THE DECISION THAT I WAS WAITING FOR: IN MY HUMBLE OPINION IT SHOWS US WHO WILL WIN THE SECOND INTERFERENCE (IDENIX). THEY WILL MAINTAIN SENIOR POSITION IN THIS INTERFERENCE AND THUS BE "ALLOWED" TO USE THEIR EARLIER DATED PATENTS.

Yes, Its all about CONSTRUCTIVE reduction to practice

Yes, a 2' Flouro 2' methyl was easily manufactured in the year 2003 to anyone "skilled in the art"

Yes, their was diligence (but, it was clearly secondary to the molecules that THE PATENT holder decided to pursue) that is their prerogative and does not mean they "lose their legal rights" to their clear IP property filed and accepted years before gilead filed .

Gilead, you should have settled!
 




see post #8:

"We will see "how well things are going" in the USPTO trial by how the BPAI responds to document 353 and 354 "CLARK REQUEST FOR REHEARING 1 & 2" submitted respectively on 4/25 & 5/01 . This should give us some clues as to how things will go with this interference. My guess: Not good for the Clark team."


Well, we just found out.......Requests Denied!
 




"'Although the district courts’ decisions in Abbott and Streck were made in the circumstances of invoking issue preclusion in the context of a § 146 action and a parallel infringement action in the district courts, the panel applies the same reasoning to the issue raised by Clark for rehearing in the instant interference. Because the § 146 action in the Delaware District Court arising from the ’871 interference may introduce new evidence and therefore constitute essentially a trial de novo, we conclude that, in this case, Storer has not yet had the opportunity to fairly and fully litigate its case and that, therefore, estoppel under Bd.R. 127(a)(1) does not apply until the § 146 action is concluded. "

Gilead is soooo Screwd now!
 












Just read his/her posts. I mean can't anyone do their own research anymore. I already knew most of what was laid out for everyone on a silver platter. Investors are just idiots these days. They even provided links...Get-a-life.
 
















if patent litigation turns bad for Gilead, the penalty is a small royalty. Gilead won't have to forfeit all Sovaldi sales times 3 as it seems to be suggested by OP.

This will take years to resolve. Good luck to Idenix because it's going to be expensive